Citadel Advisors
AXSM icon

Citadel Advisors’s Axsome Therapeutics AXSM Stock Holding History

Citadel Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.7M Sell
104,500
-71,500
-41% -$12.4M ﹤0.01% 2481
2025
Q4 		$32.1M Buy
176,000
+85,300
+94% +$11.9M ﹤0.01% 1835
2025
Q3 		$11M Sell
90,700
-6,600
-7% -$743K ﹤0.01% 3136
2025
Q2 		$10.2M Sell
97,300
-4,800
-5% -$508K ﹤0.01% 2997
2025
Q1 		$11.9M Sell
102,100
-114,100
-53% -$13M ﹤0.01% 2632
2024
Q4 		$18.3M Buy
216,200
+77,400
+56% +$7.12M ﹤0.01% 2258
2024
Q3 		$12.5M Buy
138,800
+57,300
+70% +$5M ﹤0.01% 2596
2024
Q2 		$6.56M Buy
81,500
+5,100
+7% +$378K ﹤0.01% 3352
2024
Q1 		$6.1M Sell
76,400
-34,500
-31% -$2.9M ﹤0.01% 3635
2023
Q4 		$8.83M Buy
110,900
+29,200
+36% +$1.95M ﹤0.01% 3013
2023
Q3 		$5.71M Sell
81,700
-166,300
-67% -$12.4M ﹤0.01% 3450
2023
Q2 		$17.8M Buy
248,000
+93,200
+60% +$6.88M ﹤0.01% 1999
2023
Q1 		$9.55M Sell
154,800
-329,600
-68% -$21.7M ﹤0.01% 2875
2022
Q4 		$37.4M Sell
484,400
-118,100
-20% -$7.06M 0.01% 1365
2022
Q3 		$26.9M Sell
602,500
-4,700
-0.8% -$235K 0.01% 1592
2022
Q2 		$23.3M Sell
607,200
-173,300
-22% -$5.48M 0.01% 1690
2022
Q1 		$32.3M Sell
780,500
-152,000
-16% -$4.71M 0.01% 1473
2021
Q4 		$35.2M Buy
932,500
+474,100
+103% +$17.4M 0.01% 1466
2021
Q3 		$15.1M Buy
458,400
+289,000
+171% +$11.3M ﹤0.01% 2421
2021
Q2 		$11.4M Buy
169,400
+81,600
+93% +$4.9M ﹤0.01% 2871
2021
Q1 		$4.97M Sell
87,800
-35,300
-29% -$2.48M ﹤0.01% 4272
2020
Q4 		$10M Sell
123,100
-40,900
-25% -$3.06M ﹤0.01% 2640
2020
Q3 		$11.7M Buy
164,000
+7,900
+5% +$616K ﹤0.01% 2104
2020
Q2 		$12.8M Sell
156,100
-223,800
-59% -$17.2M ﹤0.01% 1959
2020
Q1 		$22.4M Buy
379,900
+82,900
+28% +$6.75M 0.01% 1146
2019
Q4 		$30.7M Buy
297,000
+156,900
+112% +$6.34M 0.01% 1105
2019
Q3 		$2.84M Buy
140,100
+49,900
+55% +$1.28M ﹤0.01% 3944
2019
Q2 		$2.32M Buy
90,200
+47,000
+109% +$942K ﹤0.01% 4267
2019
Q1 		$615K Buy
+43,200
New +$401K ﹤0.01% 6426

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's AXSM Position: Q1 2026 in Review

Citadel Advisors increased its Axsome Therapeutics (AXSM) stake by 104% in Q1 2026, buying an estimated $24.8M and bringing the position to 281,503 shares worth $47.6M. The position accounts for 0.01% of the portfolio, ranked #1412.

Citadel Advisors first reported a position in AXSM in Q3 2016 and has held it in 31 quarters since. The position peaked at $91.3M in Q1 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Citadel Advisors held 281,503 shares of Axsome Therapeutics worth $47.6M as of Q1 2026.
  • Citadel Advisors bought 143,290 Axsome Therapeutics shares in Q1 2026, an estimated $24.8M.
  • Axsome Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1412 holding.
  • Citadel Advisors first reported a position in Axsome Therapeutics in Q3 2016 and has held it in 31 quarters since.
  • Citadel Advisors's Axsome Therapeutics position peaked at $91.3M in Q1 2024.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.